All In Biotech

Drug Trial Radar · NCT01227824

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

Last checked: Nov 19, 2026Latest source record: Oct 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 828 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

828

Actual

Start

Oct 19, 2010

Primary completion

Feb 6, 2012

Study completion Dec 27, 2016

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Shionogi; GlaxoSmithKline
First posted
Oct 25, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-naïve adult subjects.

Conditions

  • Infection, Human Immunodeficiency Virus I

Interventions

  • GSK1349572 (dolutegravir)Drug

    GSK1349572 50 mg taken once daily with or without food

  • raltegravirDrug

    raltegravir 400mg taken twice daily

  • GSK1349572 PlaceboOther

    GSK1349572 placebo taken once daily

  • ABC/3TCOther

    Abacavir/Lamivudine background therapy once daily

  • TDF/FTCOther

    Tenofovir/emtricitabine background therapy once daily

  • raltegravir PlaceboOther

    raltegravir placebo taken twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48Time frame: Baseline up to Week 48

Locations

101 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Ft. Pierce, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Hillsborough, New Jersey

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Columbia, South Carolina

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Surry Hills, New South Wales, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Hamilton, Ontario, Canada

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Garches, France

  • GSK Investigational Site

    Le Kremlin-Bicêtre, France

  • GSK Investigational Site

    Levallois-Perret, France

  • GSK Investigational Site

    Lyon, France

  • GSK Investigational Site

    Marseille, France

  • GSK Investigational Site

    Nantes, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.